"Intercept , looks like it could become first biopharma to get drug for NASH approved , although the results were somewhat mixed "

IMO results not very strong !!! about 11.2% response rate....

Obeticholic Acid clinical profile does suggest room for improvement.

Also with higher dose about 9% of patients stop treatment because of bad side effects .



All IMO